ES533931A0 - Un procedimiento para obtener un polidoma - Google Patents

Un procedimiento para obtener un polidoma

Info

Publication number
ES533931A0
ES533931A0 ES533931A ES533931A ES533931A0 ES 533931 A0 ES533931 A0 ES 533931A0 ES 533931 A ES533931 A ES 533931A ES 533931 A ES533931 A ES 533931A ES 533931 A0 ES533931 A0 ES 533931A0
Authority
ES
Spain
Prior art keywords
polydoma
procedure
obtaining
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES533931A
Other languages
English (en)
Other versions
ES8506091A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hybritech Inc
Original Assignee
Hybritech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hybritech Inc filed Critical Hybritech Inc
Publication of ES533931A0 publication Critical patent/ES533931A0/es
Publication of ES8506091A1 publication Critical patent/ES8506091A1/es
Expired legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/468Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00Preparations for testing in vivo
ES533931A 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma Expired ES8506091A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36778482A 1982-04-12 1982-04-12

Publications (2)

Publication Number Publication Date
ES533931A0 true ES533931A0 (es) 1985-06-16
ES8506091A1 ES8506091A1 (es) 1985-06-16

Family

ID=23448582

Family Applications (7)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo
ES533931A Expired ES8506091A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES521370A Granted ES521370A0 (es) 1982-04-12 1983-04-11 Un procedimiento para obtener un polidoma.
ES527963A Granted ES527963A0 (es) 1982-04-12 1983-12-12 Un procedimiento de inmunoensayo

Family Applications After (4)

Application Number Title Priority Date Filing Date
ES533930A Expired ES8603080A1 (es) 1982-04-12 1984-07-02 Un procedimiento para obtener un polidoma
ES537257A Expired ES8606655A1 (es) 1982-04-12 1984-10-31 Un procedimiento de inmunoensayo
ES538727A Expired ES8604424A1 (es) 1982-04-12 1984-12-18 Un procedimiento para obtener un hibridoma selectivamente destructible (como divisional de la solicitud de patente de invencion num 521370 presentada el 11 de abril de 1983
ES545247A Expired ES8607386A1 (es) 1982-04-12 1985-07-16 Un procedimiento para obtener un polidoma

Country Status (11)

Country Link
EP (1) EP0105360A4 (es)
JP (2) JPH0753119B2 (es)
AT (1) AT394577B (es)
AU (1) AU550486B2 (es)
CA (1) CA1213229A (es)
CH (1) CH672796A5 (es)
ES (7) ES521370A0 (es)
FI (1) FI834529A0 (es)
GB (4) GB2128631B (es)
IT (1) IT1219778B (es)
WO (1) WO1983003679A1 (es)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3177776B2 (ja) * 1988-09-27 2001-06-18 武田薬品工業株式会社 ハイブリッドモノクローナル抗体,抗体産生ポリドーマおよび抗体含有薬剤
US5292668A (en) * 1981-12-21 1994-03-08 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
IL70686A (en) * 1983-01-20 1988-07-31 Suntory Ltd Mutant tumor cell lines for use in the preparation of hybridomas and the hybridomas obtained therefrom
GB2148299B (en) * 1983-09-01 1988-01-06 Hybritech Inc Antibody compositions of therapeutic agents having an extended serum half-life
EP0467416A1 (en) * 1983-09-01 1992-01-22 Hybritech Incorporated Antibody compositions of therapeutic agents having an extended serum half-life
DE3583278D1 (de) * 1984-04-23 1991-07-25 Boston Biomed Res Inst Doppelspezifische antikoerper-determinanten.
NL8501219A (nl) * 1985-04-29 1986-11-17 Stichting Vrienden Van De Stic Immunologisch complex, de bereiding en toepassing daarvan.
EP0241907A3 (en) 1986-04-14 1989-09-13 The General Hospital Corporation Heterobifunctional antibodies and method of use
US5453269A (en) * 1986-04-14 1995-09-26 The General Hospital Corporation Heterobifunctional antibodies having dual specificity for fibrin and thrombolylic agents and methods of use
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
GB8626413D0 (en) * 1986-11-05 1986-12-03 Gilliland L K Antibodies
GB8626412D0 (en) * 1986-11-05 1986-12-03 Clark M R Antibodies
US5053226A (en) * 1987-07-15 1991-10-01 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
EP0308936B1 (en) * 1987-09-23 1994-07-06 Bristol-Myers Squibb Company Antibody heteroconjugates for the killing of HIV-infected cells
GB2218100A (en) * 1988-03-02 1989-11-08 Erling Sundrehagen Conjugates for the detection and/or quantification of antigenic substances in body fluids
US4892824A (en) * 1988-03-15 1990-01-09 Synbiotics Corporation Fast track method for producing monoclonal bi-specific immunoglobulins
US5582862A (en) 1988-04-04 1996-12-10 General Hospital Corporation Antibodies that bind to α2-antiplasmin crosslinked to fibrin which do not inhibit plasma α2-antiplasmin
US5372812A (en) * 1988-04-04 1994-12-13 The General Hospital Corporation Composition and method for acceleration of clot lysis
JPH02196799A (ja) * 1988-04-08 1990-08-03 Agency Of Ind Science & Technol 抗ヒト癌蛋白複合体
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
IT1235349B (it) * 1988-12-23 1992-06-30 Biodata Spa Saggio immunologico per determinazioni in fase omogenea
CA2006408A1 (en) * 1988-12-27 1990-06-27 Susumu Iwasa Bispecific monoclonal antibody, its production and use
US5217713A (en) * 1988-12-27 1993-06-08 Takeda Chemical Industries, Ltd. Cytotoxic bispecific monoclonal antibody, its production and use
WO1990012109A1 (en) * 1989-03-30 1990-10-18 Board Of Regents, The University Of Texas System Monoclonal antibodies binding platinum complexes
FR2652004B1 (fr) * 1989-09-21 1994-10-28 Immunotech Partners Nouveaux derives hydrophiles, application au diagnostic et a la therapeutique, kits diagnostiques ou therapeutiques et reactifs immunologiques.
EP0515571B1 (en) * 1990-02-16 1998-12-02 Boston Biomedical Research Institute Hybrid reagents capable of selectively releasing molecules into cells
TW212184B (es) * 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5573920A (en) * 1991-04-26 1996-11-12 Surface Active Limited Antibodies, and methods for their use
GB9316369D0 (en) * 1993-08-06 1993-09-22 Surface Active Ltd Diagnostic method
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
GB9421468D0 (en) * 1994-10-18 1994-12-07 Surface Active Ltd Biosensor
CA2266339A1 (en) * 1996-09-20 1998-03-26 The General Hospital Corporation Chimeric, humanized and single chain antibodies to alpha-2-antiplasmin
US20020132274A1 (en) 2001-01-17 2002-09-19 Nevalainen Marja T. Diagnostic and monitorings methods for cancer
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
AU2005222947B2 (en) 2004-03-16 2010-12-23 Onconova Therapeutics Inc. Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド N末端にアミノ安息香酸単位を有するオーリスタチン
CA2605507C (en) 2005-04-19 2016-06-28 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
WO2007011968A2 (en) 2005-07-18 2007-01-25 Seattle Genetics, Inc. Beta-glucuronide-linker drug conjugates
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
CA2673851C (en) 2007-01-22 2016-05-03 Genentech, Inc. Polyelectrolyte precipitation and purification of proteins
CA2975228C (en) 2008-05-02 2020-07-21 Seattle Genetics, Inc. Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation
WO2011133658A1 (en) 2010-04-22 2011-10-27 Boston Medical Center Corporation Compositions and methods for targeting and delivering therapeutics into cells
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CN105358174B (zh) 2013-03-15 2019-03-15 酵活有限公司 具细胞毒性和抗有丝分裂的化合物以及其使用方法
US10227407B2 (en) 2013-10-10 2019-03-12 Yukinari Kato Anti-podoplanin antibody
AU2014373574B2 (en) 2013-12-27 2020-07-16 Zymeworks Bc Inc. Sulfonamide-containing linkage systems for drug conjugates
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
TWI618697B (zh) 2015-11-03 2018-03-21 財團法人工業技術研究院 化合物、連接子-藥物、及配體-藥物耦合體
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
JP2020512312A (ja) 2017-03-24 2020-04-23 シアトル ジェネティックス, インコーポレイテッド グルクロニド薬物−リンカーの調製のためのプロセスおよびその中間体
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CA3110096A1 (en) * 2018-08-30 2020-03-05 Innovative Cellular Therapeutics CO., LTD. Chimeric antigen receptor cells for treating solid tumor
CN114173824A (zh) 2019-05-10 2022-03-11 武田药品工业株式会社 抗体药物缀合物
TW202138388A (zh) 2019-12-30 2021-10-16 美商西根公司 以非海藻糖苷化抗-cd70抗體治療癌症之方法
WO2022097117A1 (en) 2020-11-09 2022-05-12 Takeda Pharmaceutical Company Ltd. Antibody drug conjugates
KR20240025597A (ko) 2021-06-29 2024-02-27 씨젠 인크. 비푸코실화 항-cd70 항체 및 cd47 길항제의 조합으로 암을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130634A (en) * 1974-03-15 1978-12-19 University Of Illinois Foundation Method for detecting and quantifying antigens
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies

Also Published As

Publication number Publication date
GB2168998B (en) 1987-03-04
GB2167086A (en) 1986-05-21
ES8607386A1 (es) 1986-05-16
ES8503441A1 (es) 1985-02-16
ES545247A0 (es) 1986-05-16
GB8530309D0 (en) 1986-01-22
EP0105360A4 (en) 1986-07-08
JPH0753119B2 (ja) 1995-06-07
ES538727A0 (es) 1986-02-01
EP0105360A1 (en) 1984-04-18
ES527963A0 (es) 1985-02-16
ES8504461A1 (es) 1985-04-16
AU1555983A (en) 1983-11-04
JPH0753600A (ja) 1995-02-28
IT8320548A0 (it) 1983-04-12
ES537257A0 (es) 1986-04-01
IT1219778B (it) 1990-05-24
ES8604424A1 (es) 1986-02-01
FI834529A (fi) 1983-12-09
ES8506091A1 (es) 1985-06-16
JP2562002B2 (ja) 1996-12-11
FI834529A0 (fi) 1983-12-09
ES521370A0 (es) 1985-04-16
JPS6312276A (ja) 1988-01-19
GB2168998A (en) 1986-07-02
GB2128631B (en) 1987-02-25
WO1983003679A1 (en) 1983-10-27
ES533930A0 (es) 1985-12-01
GB2167086B (en) 1987-03-04
GB2169921B (en) 1987-03-04
GB2169921A (en) 1986-07-23
ATA901883A (de) 1991-10-15
AU550486B2 (en) 1986-03-20
ES8606655A1 (es) 1986-04-01
CA1213229A (en) 1986-10-28
ES8603080A1 (es) 1985-12-01
GB8530308D0 (en) 1986-01-22
GB8332646D0 (en) 1984-01-11
AT394577B (de) 1992-05-11
CH672796A5 (es) 1989-12-29
GB8530310D0 (en) 1986-01-22
GB2128631A (en) 1984-05-02

Similar Documents

Publication Publication Date Title
ES545247A0 (es) Un procedimiento para obtener un polidoma
ES500726A0 (es) Un procedimiento para preparar diaminopiridinas
ES532536A0 (es) Un procedimiento para preparar un derivado de carbostirilo
ES523195A0 (es) Un procedimiento para preparar alquil-glicosidos
ES537668A0 (es) Un procedimiento para preparar n-formil-3-fenoxi-1-azetidincarboxamidas
ES530024A0 (es) Un procedimiento para preparar derivados de pirazinona
ES527790A0 (es) Un procedimiento para preparar nuevos compuestos de cefem
ES500727A0 (es) Un procedimiento para preparar imidazo-piridinas
ES545270A0 (es) Un procedimiento para la obtencion de piridoindoles
ES528304A0 (es) Un procedimiento para preparar derivados de pirimidona
ES534297A0 (es) Un procedimiento para preparar derivados de cefem
ES519652A0 (es) Un procedimiento para obtener s-adenosil-metionina.
ES524245A0 (es) Procedimiento para obtener un polipeptido
ES523193A0 (es) Un procedimiento para preparar 3-fenoxi-1-azetidincarbo-xznmidas
MX163078B (es) Procedimiento mejorado para formar nitroparafinas
ES527237A0 (es) Un procedimiento para producir derivados de tiazol
ES524200A0 (es) Un procedimiento para preparar compuestos peptidicos sustituidos
ES527278A0 (es) Un procedimiento para obtener 2,5-anhidro-3,4,6-tri-o-acil-d-alonselenocarboxamida
ES526177A0 (es) Un procedimiento para preparar derivados de pirimidona
ES500464A0 (es) Un procedimiento para preparar 2-halogeno-acetanilidas
ES527108A0 (es) Un procedimiento para preparar 2-alcoxi-5-(piridinil) piridinas
ES527738A0 (es) Un procedimiento para preparar derivados de piridona
ES525647A0 (es) Un procedimiento para preparar compuestos de benzoilurea
ES518376A0 (es) Un procedimiento para preparar nuevas nitro-n-fenilpiridinaminas
ES527789A0 (es) Un procedimiento para preparar derivados de cicloalquenilo

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 19970519